Skeletal complications and survival in renal cancer patients with bone metastases

Bone

Volumn 48, Issue 1, 2011, Pages 160-166

  Woodward, Emma ^a,d   Jagdev, Satinder ^b   McParland, Lucy ^c   Clark, Katy ^b   Gregory, Walter ^c   Newsham, Alex ^b   Rogerson, Suzanne ^b   Hayward, Kate ^b   Selby, Peter ^a   Brown, Janet ^a,d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bone metastases; Renal cancer; Renal cell carcinoma; Skeletal complications; Spinal cord compression

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DRUG USE; FEMALE; FRACTURE; HUMAN; HYPERCALCEMIA; INCIDENCE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NERVE ROOT COMPRESSION; SPINAL CORD COMPRESSION;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SPINAL CORD COMPRESSION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 78650306312     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.09.008     Document Type: Article

References (25)

1. Ferlay J.B.F., Pisani P., Parkin D.M. Cancer incidence, mortality and prevalence worldwide. "GLOBOCAN2002" IARC CancerBase No. 5 Version 2.0 2000.
2. Szendroi A., Dinya E., Kardos M., Szasz A.M., Nemeth Z., Ats K., et al. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol Oncol Res 2010, 16:29-38.
3. Zekri J., Ahmed N., Coleman R.E., Hancock B.W. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001, 19:379-382.
4. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
5. Kozlowski J. Management of distant solitary recurrence in the patient with renal cancer. Urol Clin North Am 2004, 21:601-624.
6. Lipton A., Colombo-Berra A., Bukowski R.M., Rosen L., Zheng M., Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004, 10:6397S-6403S.
7. Althausen P., Althausen A., Jennings L.C., Mankin H.J. Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 1997, 80:1103-1109.
8. Koga S., Tsuda S., Nishikido M., Ogawa Y., Hayashi K., Hayashi T., et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 2001, 166:2126-2128.
9. Smith M.R. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005, 31(Suppl 3):19-25.
10. Lipton A., Cook R., Saad F., Major P., Garnero P., Terpos E., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
11. Jung S.T., Ghert M.A., Harrelson J.M., Scully S.P. Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 2003, 409:223-231.
12. Coleman R.E. Risks and benefits of bisphosphonates. Br J Cancer 2008, 98:1736-1740.
13. Lipton A., Zheng M., Seamen J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:962-969.
14. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
15. Denoyelle C., Hong L., Vannier J.P., Soria J., Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003, 88:1631-1640.
16. Kaplan E.L., Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 1958, 53:457-481.
17. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977, 35:1-39.
18. Theriault R.L., Lipton A., Hortobagyi G.N., Leff R., Glück S., Stewart J.F., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999, 17:846-854.
19. Schlesinger-Raab A., Treiber U., Zaak D., Hölzel D., Engel J. Metastatic renal cell carcinoma: results of a population-based study with 25years follow-up. Eur J Cancer 2008, 44:2485-2495.
20. Major P.P., Cook R.J., Lipton A., Smith M.R., Terpos E., Coleman R.E. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer 2009, 9:272.
21. Lipton A., Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008, 2:197-203.
22. Henry D., von Moos R., Vadhan-Raj S., Hungria V., Spencer A., Hirsh V., et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 2009, 7:11.
23. Christodoulou C., Pervena A., Klouvas G., Galani E., Falagas M.E., Tsakalos G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76:209-221.
24. Ayllon J., Launay-Vacher V., Medioni J., Cros C., Spano J.P., Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?. Ann Oncol 2009, 20:600-601.
25. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.